大剂量冠状动脉内腺苷注射在分数血流储备评估中的有效性和安全性

IF 1.8 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Acta Cardiologica Sinica Pub Date : 2022-09-01 DOI:10.6515/ACS.202209_38(5).20220309A
Chien-Boon Jong, Min-Tsun Liao, Tsui-Shan Lu, Shih-Wei Meng, Chun-Kai Chen, Ya-Chin Tsai, Jui-Cheng Kuo, Chih-Cheng Wu
{"title":"大剂量冠状动脉内腺苷注射在分数血流储备评估中的有效性和安全性","authors":"Chien-Boon Jong, Min-Tsun Liao, Tsui-Shan Lu, Shih-Wei Meng, Chun-Kai Chen, Ya-Chin Tsai, Jui-Cheng Kuo, Chih-Cheng Wu","doi":"10.6515/ACS.202209_38(5).20220309A","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The recommended dosage of intracoronary adenosine in fractional flow reserve (FFR) assessment is controversial. High-dose adenosine may overcome the biological variability of adenosine response in hyperemia.</p><p><strong>Objectives: </strong>We aimed to test the efficacy and safety of a high-dose escalation protocol at our institute.</p><p><strong>Methods: </strong>Using the adenosine dose escalation protocol, the percentages of FFR ≤ 0.75 and 0.80 after high-dose escalation were compared with those at conventional doses. The chi-squared test was used to evaluate the accuracy of FFR values with the tested doses by comparing them with the results of a non-invasive pretest.</p><p><strong>Results: </strong>A total of 87 patients (130 vessels) were included, and protocol adherence was 93.1%. High-dose intracoronary adenosine was injected in 78.5% of the vessels. The dose escalation strategy was well-tolerated without serious complications. The positive rate increased significantly after conducting the protocol compared to that with a conventional dose (28.2% vs. 23.6% with an FFR threshold of 0.75, and 48.7% vs. 42.5% with a threshold of 0.80, both p < 0.05). In the validation cohort, only FFR ≤ 0.75 was associated with the binary result of the non-invasive pretest (p < 0.01 vs. p = 0.37). The high-dose adenosine escalation strategy did not increase the accuracy of FFR (77.8% vs. 75.6% in conventional dose and high-dose adenosine, respectively).</p><p><strong>Conclusions: </strong>The use of a high-dose escalation strategy increased the positive rate in FFR assessments.</p>","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"38 5","pages":"553-563"},"PeriodicalIF":1.8000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479048/pdf/acs-38-553.pdf","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of High-Dose Intracoronary Adenosine Injection in Fractional Flow Reserve Assessment.\",\"authors\":\"Chien-Boon Jong, Min-Tsun Liao, Tsui-Shan Lu, Shih-Wei Meng, Chun-Kai Chen, Ya-Chin Tsai, Jui-Cheng Kuo, Chih-Cheng Wu\",\"doi\":\"10.6515/ACS.202209_38(5).20220309A\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The recommended dosage of intracoronary adenosine in fractional flow reserve (FFR) assessment is controversial. High-dose adenosine may overcome the biological variability of adenosine response in hyperemia.</p><p><strong>Objectives: </strong>We aimed to test the efficacy and safety of a high-dose escalation protocol at our institute.</p><p><strong>Methods: </strong>Using the adenosine dose escalation protocol, the percentages of FFR ≤ 0.75 and 0.80 after high-dose escalation were compared with those at conventional doses. The chi-squared test was used to evaluate the accuracy of FFR values with the tested doses by comparing them with the results of a non-invasive pretest.</p><p><strong>Results: </strong>A total of 87 patients (130 vessels) were included, and protocol adherence was 93.1%. High-dose intracoronary adenosine was injected in 78.5% of the vessels. The dose escalation strategy was well-tolerated without serious complications. The positive rate increased significantly after conducting the protocol compared to that with a conventional dose (28.2% vs. 23.6% with an FFR threshold of 0.75, and 48.7% vs. 42.5% with a threshold of 0.80, both p < 0.05). In the validation cohort, only FFR ≤ 0.75 was associated with the binary result of the non-invasive pretest (p < 0.01 vs. p = 0.37). The high-dose adenosine escalation strategy did not increase the accuracy of FFR (77.8% vs. 75.6% in conventional dose and high-dose adenosine, respectively).</p><p><strong>Conclusions: </strong>The use of a high-dose escalation strategy increased the positive rate in FFR assessments.</p>\",\"PeriodicalId\":6957,\"journal\":{\"name\":\"Acta Cardiologica Sinica\",\"volume\":\"38 5\",\"pages\":\"553-563\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479048/pdf/acs-38-553.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Cardiologica Sinica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.6515/ACS.202209_38(5).20220309A\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Cardiologica Sinica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.6515/ACS.202209_38(5).20220309A","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:冠状动脉内腺苷在分数血流储备(FFR)评估中的推荐剂量存在争议。大剂量腺苷可克服高血流状态下腺苷反应的生物变异性:我们的目的是在本研究所测试高剂量升级方案的有效性和安全性:方法:采用腺苷剂量递增方案,将高剂量递增后FFR≤0.75和0.80的百分比与常规剂量进行比较。通过与无创预检结果进行比较,采用卡方检验来评估测试剂量下 FFR 值的准确性:结果:共纳入87名患者(130条血管),方案依从性为93.1%。78.5%的血管注射了高剂量冠脉内腺苷。剂量升级策略的耐受性良好,未出现严重并发症。与常规剂量相比,采用该方案后阳性率明显增加(FFR阈值为0.75时为28.2%对23.6%,阈值为0.80时为48.7%对42.5%,P均<0.05)。在验证队列中,只有 FFR ≤ 0.75 与无创预检的二元结果相关(p < 0.01 vs. p = 0.37)。大剂量腺苷升级策略并未提高FFR的准确率(常规剂量和大剂量腺苷的准确率分别为77.8%和75.6%):结论:使用大剂量腺苷升级策略提高了FFR评估的阳性率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Efficacy and Safety of High-Dose Intracoronary Adenosine Injection in Fractional Flow Reserve Assessment.

Background: The recommended dosage of intracoronary adenosine in fractional flow reserve (FFR) assessment is controversial. High-dose adenosine may overcome the biological variability of adenosine response in hyperemia.

Objectives: We aimed to test the efficacy and safety of a high-dose escalation protocol at our institute.

Methods: Using the adenosine dose escalation protocol, the percentages of FFR ≤ 0.75 and 0.80 after high-dose escalation were compared with those at conventional doses. The chi-squared test was used to evaluate the accuracy of FFR values with the tested doses by comparing them with the results of a non-invasive pretest.

Results: A total of 87 patients (130 vessels) were included, and protocol adherence was 93.1%. High-dose intracoronary adenosine was injected in 78.5% of the vessels. The dose escalation strategy was well-tolerated without serious complications. The positive rate increased significantly after conducting the protocol compared to that with a conventional dose (28.2% vs. 23.6% with an FFR threshold of 0.75, and 48.7% vs. 42.5% with a threshold of 0.80, both p < 0.05). In the validation cohort, only FFR ≤ 0.75 was associated with the binary result of the non-invasive pretest (p < 0.01 vs. p = 0.37). The high-dose adenosine escalation strategy did not increase the accuracy of FFR (77.8% vs. 75.6% in conventional dose and high-dose adenosine, respectively).

Conclusions: The use of a high-dose escalation strategy increased the positive rate in FFR assessments.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta Cardiologica Sinica
Acta Cardiologica Sinica 医学-心血管系统
CiteScore
2.90
自引率
15.80%
发文量
144
审稿时长
>12 weeks
期刊介绍: Acta Cardiologica Sinica welcomes all the papers in the fields related to cardiovascular medicine including basic research, vascular biology, clinical pharmacology, clinical trial, critical care medicine, coronary artery disease, interventional cardiology, arrythmia and electrophysiology, atherosclerosis, hypertension, cardiomyopathy and heart failure, valvular and structure cardiac disease, pediatric cardiology, cardiovascular surgery, and so on. We received papers from more than 20 countries and areas of the world. Currently, 40% of the papers were submitted to Acta Cardiologica Sinica from Taiwan, 20% from China, and 20% from the other countries and areas in the world. The acceptance rate for publication was around 50% in general.
期刊最新文献
18F-Florbetaben PET/CT for the Diagnosis and Subtyping of Cardiac Amyloidosis: A Case Series and Review of the Literature. 2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part I. 2024 Update of the TSOC Expert Consensus of Fabry Disease. A Look is Worth a Thousand Words!! - Case Series of Forearm Compartment Syndrome after Transradial Coronary Intervention. A Strongly Suspected Case of Concomitant Myocarditis in Naegleria fowleri Induced Primary Amoebic Meningoencephalitis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1